X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11585) 11585
Book Review (1431) 1431
Publication (827) 827
Conference Proceeding (41) 41
Magazine Article (16) 16
Dissertation (8) 8
Book Chapter (5) 5
Trade Publication Article (2) 2
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10925) 10925
index medicus (10786) 10786
deoxycytidine - analogs & derivatives (10648) 10648
deoxycytidine - administration & dosage (8254) 8254
female (7303) 7303
oncology (6515) 6515
male (6165) 6165
middle aged (6074) 6074
antineoplastic combined chemotherapy protocols - therapeutic use (5740) 5740
aged (5625) 5625
adult (4589) 4589
chemotherapy (4200) 4200
gemcitabine (3954) 3954
treatment outcome (3439) 3439
cancer (3145) 3145
capecitabine (2788) 2788
deoxycytidine - adverse effects (2735) 2735
fluorouracil - analogs & derivatives (2655) 2655
deoxycytidine - therapeutic use (2628) 2628
fluorouracil - administration & dosage (2442) 2442
antineoplastic combined chemotherapy protocols - adverse effects (2408) 2408
cisplatin - administration & dosage (1987) 1987
pancreatic neoplasms - drug therapy (1944) 1944
aged, 80 and over (1842) 1842
lung neoplasms - drug therapy (1700) 1700
antimetabolites, antineoplastic - administration & dosage (1689) 1689
cisplatin (1686) 1686
drug administration schedule (1665) 1665
therapy (1592) 1592
animals (1562) 1562
neoplasm staging (1540) 1540
pharmacology & pharmacy (1467) 1467
pancreatic cancer (1454) 1454
disease-free survival (1435) 1435
care and treatment (1401) 1401
antineoplastic combined chemotherapy protocols - administration & dosage (1375) 1375
antimetabolites, antineoplastic - therapeutic use (1369) 1369
carcinoma, non-small-cell lung - drug therapy (1352) 1352
survival rate (1330) 1330
survival (1301) 1301
carcinoma (1296) 1296
trial (1281) 1281
pancreatic neoplasms - pathology (1260) 1260
adenocarcinoma - drug therapy (1191) 1191
survival analysis (1176) 1176
research (1162) 1162
medicine & public health (1141) 1141
organoplatinum compounds - administration & dosage (1095) 1095
paclitaxel - administration & dosage (1094) 1094
combination (1075) 1075
breast neoplasms - drug therapy (1071) 1071
deoxycytidine - pharmacology (1045) 1045
mice (1042) 1042
cell line, tumor (1039) 1039
prognosis (1034) 1034
dose-response relationship, drug (1020) 1020
retrospective studies (1013) 1013
combined modality therapy (978) 978
antimetabolites, antineoplastic - adverse effects (911) 911
paclitaxel (910) 910
5-fluorouracil (896) 896
drug therapy (891) 891
neoplasm metastasis (876) 876
antineoplastic agents (873) 873
metastasis (857) 857
fluorouracil - adverse effects (837) 837
adenocarcinoma (834) 834
antimitotic agents (828) 828
analysis (809) 809
clinical trials (794) 794
oxaliplatin (782) 782
hematology, oncology and palliative medicine (778) 778
lung neoplasms - pathology (778) 778
taxoids - administration & dosage (777) 777
tumors (755) 755
disease progression (753) 753
fluorouracil (745) 745
follow-up studies (731) 731
carboplatin - administration & dosage (725) 725
antineoplastic agents - therapeutic use (719) 719
antineoplastic agents - administration & dosage (713) 713
phase-ii (707) 707
chemotherapy, adjuvant (696) 696
fluorouracil - therapeutic use (696) 696
docetaxel (689) 689
breast neoplasms - pathology (686) 686
radiotherapy (685) 685
colorectal neoplasms - drug therapy (674) 674
phase-ii trial (673) 673
cancer research (654) 654
time factors (653) 653
health aspects (644) 644
adenocarcinoma - pathology (629) 629
kaplan-meier estimate (629) 629
vinblastine - administration & dosage (629) 629
surgery (628) 628
dosage and administration (625) 625
camptothecin - analogs & derivatives (620) 620
toxicity (618) 618
administration, oral (606) 606
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10640) 10640
Japanese (503) 503
Chinese (128) 128
French (105) 105
German (79) 79
Russian (43) 43
Spanish (35) 35
Italian (28) 28
Hungarian (15) 15
Dutch (5) 5
Polish (5) 5
Czech (4) 4
Lithuanian (4) 4
Danish (2) 2
Hebrew (2) 2
Portuguese (2) 2
Romanian (2) 2
Bosnian (1) 1
Korean (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 4/2008, Volume 100, Issue 8, pp. 542 - 551
Background Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of... 
THERAPY | GEPARDUO | ONCOLOGY | PROGNOSIS | CARCINOMA | CHEMOTHERAPY | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Vinblastine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Carcinoma, Ductal, Breast - drug therapy | Fluorouracil - administration & dosage | Vinblastine - analogs & derivatives | Mastectomy, Segmental | Adult | Female | Breast Neoplasms - diagnostic imaging | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Deoxycytidine - administration & dosage | Ultrasonography, Mammary | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Carcinoma, Lobular - drug therapy | Patient Compliance | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Germany | Chemotherapy | Breast cancer | Drug therapy | Comparative analysis | Health aspects | Cancer | Side effects | Toxicity | Clinical outcomes | Index Medicus
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Summary Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 6, pp. 509 - 518
Preventing HIV-1 infection is a high global priority. This study assessed prevention strategies in young women in South Africa, Uganda, and Zimbabwe using oral... 
TRIALS | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | ANTIRETROVIRAL PROPHYLAXIS | MICROBICIDE | PREVENTION | ADHERENCE | GEL | HIV Infections - prevention & control | Humans | Middle Aged | Drug Resistance, Viral | Administration, Intravaginal | Deoxycytidine - blood | Adenine - blood | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Organophosphonates - blood | Surveys and Questionnaires | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | HIV Seropositivity | Administration, Oral | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Anti-Retroviral Agents - adverse effects | Organophosphonates - adverse effects | Africa South of the Sahara | Adenine - administration & dosage | Pre-Exposure Prophylaxis | Organophosphonates - administration & dosage | Medication Adherence | Anti-Retroviral Agents - administration & dosage | Adolescent | HIV Infections - complications | Deoxycytidine - analogs & derivatives | Women | Care and treatment | HIV infection in women | Dosage and administration | HIV infection | Health aspects | Risk factors | Intervention | Creatinine | Antiretroviral drugs | Motivation | Human immunodeficiency virus--HIV | Prophylaxis | Vagina | Infections | Preventive medicine | Index Medicus | Abridged Index Medicus
Journal Article